Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Costa, Luciano J., Maddocks, Kami, Epperla, Narendranath, Reddy, Nishitha M., Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha J., Chavez, Julio C., Calzada, Oscar, Lansigan, Frederick, Nasheed, Hossain, Barta, Stefan K., Zhou, Zheng, Jaglal, Michael, Chhabra, Saurabh, Hernandez-Ilizaliturri, Francisco, Xavier, Ana C., Mehta, Amitkumar, Peker, Deniz, Forero-Torres, Andreas, Al-Mansour, Zeina, Evens, Andrew M., Cohen, Jonathon B., Flowers, Christopher R., Fenske, Timothy S., Hamadani, Mehdi
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549936/
https://ncbi.nlm.nih.gov/pubmed/27880984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24615
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados